Nachrichten zur Eli Lilly & Co Aktie

Can Novo Nordisk Sustain Its GLP-1 Edge Amid Lillys Growing Pressure?

NVO beats Q1 estimates and raises its 2026 outlook. Meanwhile, Eli Lillys expanding GLP-1 portfolio threatens its obesity market dominance.…

Should Eli Lilly Investors Worry About Its Newest Rival -- From Within?

Eli Lilly is dominating one of the biggest growth markets in healthcare: the weight loss drug market.…

GLP-1 Wars: Winners & Losers

With its best-in-breed GLP-1 drugs, Eli Lilly is beginning to cement itself as the dominant player in the massive GLP-1…

Should Hims & Hers Health’s AI and GLP-1 Push Require Action From Hims & Hers Health (HIMS) Investors?

In recent weeks, Hims & Hers Health launched its Labs AI agent to help users interpret biomarker lab results, expanded…

Why Eli Lilly (LLY) is a Top Momentum Stock for the Long-Term

Whether youre a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top…

NVO Rallies 21% in a Month: How Should Investors Play the Stock?

Novo Nordisk stock jumps 21% in a month after a Q1 beat and stronger GLP-1 demand, but pricing pressure and…

Hims Labs AI And GLP 1 Push Test Stock Valuation Story

Hims & Hers Health (NYSE:HIMS) has launched Labs AI, an AI care agent that provides users with personalized, clinically vetted…

Eli Lilly: Strong Buy Raised Revenue Guidance By $2 Billion For 2026 And Label Expansions

…

Eli Lilly: Investing US$4.5bn for GLP-1 Medicine Production

Eli Lilly is investing an additional US$4.5bn to expand its Lebanon, Indiana sites for GLP-1 drugs and genetic medicines amid…

Will Eli Lilly Be the First $2 Trillion Healthcare Stock? 3 Catalysts That Could Get It There.

The competition is far behind.…

Eli Lilly Now Has the Worlds Best-Selling Drug -- But Does That Make the Stock a No-Brainer Buy?

Mounjaro generated $8.66 billion in sales in the first quarter.…

What the FDAs Latest Proposal Means for Lilly, Novo, and Hims

The FDAs latest proposal would be a win for Eli Lilly and Novo Nordisk, while Hims & Hers Health would…

Novo and Lilly gain on signs weight-loss pills could expand the market

Early data from weight-loss pills are lifting shares in Novo Nordisk and Eli Lilly as investors bet that easier-to-take drugs…

Eli Lilly stock swings after FDA liver failure report for GLP-1 drug

Eli Lilly (LLY) stock initially sold off on Monday morning, May 4, after the FDA disclosed a liver failure report…

Lilly commits additional $4.5 billion across Indiana manufacturing sites

Eli Lilly said on ?Wednesday it would commit an additional $4.5 billion ?investment across two of its three sites in…

Top Research Reports for Eli Lilly, Western Digital & Vertiv

Eli Lillys strong GLP-1 drug demand and pipeline advances drive growth, while Western Digital and Vertiv ride AI-fueled momentum and…

3 Reasons Its Not Too Late to Buy Eli Lilly Stock

The company still has a strong lead in its core therapeutic area.…

Novo Nordisk’s head start on GLP-1 pills forces investors to rethink Eli Lillys dominance

Early signs from the launch of Novo Nordisks Wegovy pill and Eli Lilly & Co.s Foundayo are making investors rethink…

Whats behind Eli Lillys down-and-up day after last weeks post-earnings surge

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of…

Why Eli Lilly stock is down 3% today: FDA adverse event data explained

Why Eli Lilly stock is down 3% today: FDA adverse event data explained…

Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering

PHILADELPHIA, May 04, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage…

Eli Lilly Just Announced Fantastic News for Shareholders

Lillys weight loss drugs have been delivering blockbuster revenue.…

Novo Nordisk Before Q1 Earnings: How Should Investors Play the Stock?

NVO heads into Q1 with strong GLP-1 drug demand and new Wegovy pill rollout, but pricing pressure, weak guidance and…

Eli Lilly and Company 2026 Q1 - Results - Earnings Call Presentation

…

BofA sees more upside in Eli Lilly stock

Eli Lilly’s first-quarter report gave Wall Street another reason to stay optimistic about one of the market’s biggest pharmaceutical winners,…

Eli Lilly: Buying Opportunity Knocking On The Front Door Again (Rating Upgrade)

…

ResMed (RMD) Q3 2026 Earnings Transcript

Image source: The Motley Fool.DateApr. 30, 2026, 4:30 p.m. ETCall participantsChief Executive Officer — Michael J. FarrellChief Financial Officer —…

Eli Lilly shares surge on a beat-and-raise, proving the stocks swoon was a mistake

Eli Lilly entered Thursday well off its highs. A blowout quarter shows the market got this one wrong.…

Stocks making the biggest moves midday: Blue Owl, Qualcomm, Hertz, Eli Lilly, Meta Platforms, Microsoft & more

Here are the stocks making headlines in midday trading.…

ROUNDUP 2: Überraschend starkes Quartal für Lilly - Ziele angehoben

(Kurs aktualisiert) INDIANAPOLIS (dpa-AFX) - Der US-Pharmakonzern Lilly hat dank der ungebrochen…

Eli Lilly (LLY) – Der Pharmariese entfacht mit Abnehm-Medikamenten neuen Wachstumsrausch und hebt Jahresprognose deutlich an!

Eli Lilly liefert ein Quartal zum Staunen: Umsatz +56 % auf 19,8 Mrd. USD, EPS bei 8,55 USD weit über…

dpa-AFX ProFeed